Akèy › Limfòm Non-Hodgkin › Maryland
Etid klinik pou Limfòm Non-Hodgkin nan Maryland
21 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2
Laj 3 a 39 · Tout sèks · Mizajou Sep 30, 2026 · NCT05442515A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 111, Bethesda
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05645107A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- American Oncology Partners of Maryland Pa, Bethesda
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT02682667Tissue Collection for Studies of Lymph Cancer
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT01676805Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT03223610Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 120 · Tout sèks · Mizajou Sep 25, 2026 · NCT05907759Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06398457Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT01087333Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04002947Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Maryland, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT03666000Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
- Walter Reed National Military Medical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 4 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07652580Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Aug 25, 2026 · NCT05389423A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- American Oncology Partners of Maryland, PA, Bethesda
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05254743Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Johns Hopkins, Baltimore
- Nih/Niaid, Bethesda
- Nih/Nhlbi, Bethesda
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- The Center for Cancer and Blood Disorders (CCBD), Bethesda
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 24, 2026 · NCT04068597Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Christiana Care - Union Hospital, Elkton
- ak 3 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- ak 1 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.